Trials / Terminated
TerminatedNCT04326790
The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- National and Kapodistrian University of Athens · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question arises whether colchicine, administered in a relatively low dose, could potentially have an effect the patients' clinical course by limiting the myocardial necrosis and pneumonia development in the context of COVID-19. If present, this effect would be attributed to its potential to inhibit inflammasome and (less probably) to the process of SARS-CoV-2 endocytosis in myocardial and endothelial respiratory cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colchicine | Low-dose colchicine treatment, 0.5 mg bid |
| DRUG | Standard treatment | Standard treatment |
Timeline
- Start date
- 2020-04-03
- Primary completion
- 2020-04-27
- Completion
- 2020-04-27
- First posted
- 2020-03-30
- Last updated
- 2021-04-06
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT04326790. Inclusion in this directory is not an endorsement.